

Silva Pharmaceuticals Limited


Un-Audited Financial Statements (Half Yearly)

For the Period from 01 July, 2021 to 31 December, 2021


SILVA PHARMACEUTICALS LTD.
Statement of Financial Position
As at 31 December, 2021

Particulars	Notes	Amount in Taka	
		31-Dec-21	30-Jun-21
ASSETS			
Non Current Assets		1,454,458,885	1,372,217,229
Property, Plant & Equipment	3.00	1,214,629,518	1,175,793,246
Intangible Assets	4.00	1,595,894	1,679,888
Right-of-use asset (ROU)	5.00	13,941,446	16,275,117
Capital work-in-Progress	6.00	224,292,027	178,468,978
Current Assets		1,084,926,213	1,074,937,836
Inventories	7.00	465,219,061	464,181,830
Trade and Other Receivables	8.00	273,951,604	272,213,765
Advances, Deposits and Prepayments	9.00	82,174,526	68,212,863
Fixed Deposits Receipts (FDR)	10.00	224,617,556	211,666,669
Cash and Cash Equivalents	11.00	38,963,466	58,662,709
Total Assets		2,539,385,098	2,447,155,065
SHAREHOLDERS EQUITY AND LIABILITIES:			
Equity attributable to the Shareholders		2,339,362,093	2,270,472,128
Share Capital	12.00	1,365,000,000	1,365,000,000
Retained Earnings	13.00	974,362,093	905,472,128
Non-Current Liabilities		89,212,561	88,198,786
Deferred Tax Liabilities	14.00	82,309,241	80,303,550
Lease liabilities	15.00	6,903,320	7,895,236
Current Liabilities		110,810,444	88,484,151
Lease liabilities	15.00	4,331,526	5,673,281
Trade and Other Payables	16.00	6,139,991	6,253,488
Unclaimed Dividend Account	17.00	1,487,935	1,519,762
Short Term Loan		29,070,459	29,136,805
Provision for Expenses	18.00	69,780,533	45,900,814
Total Liabilities		200,023,005	176,682,937.0
Total Equity & Liabilities:		2,539,385,098	2,447,155,065
Net Assets Value (NAV) per share	27.00	17.14	16.63

The annexed notes (1-39) form an integral part of these financial statements.



Chairman



Managing Director



Director



Chief Financial Officer



Company Secretary

Place: Dhaka;

Dated: January 27, 2022


Silva Pharmaceuticals Ltd

Statements of Profit or Loss and Other Comprehensive Income


For the Half-Year ended 31 December, 2021

Particulars	Notes	Amount in Taka			
		Half-Yearly Results		Quarterly Results	
		01/07/2021 to 31/12/2021	01/07/2020 to 31/12/2020	01/10/2021 to 31/12/2021	01/10/2020 to 31/12/2020
Turnover		411,815,560	418,427,878	195,963,807	190,905,541
Cost of goods sold	19.00	(236,850,664)	(243,742,218)	(115,865,042)	(116,489,861)
Gross Profit		174,964,896	174,685,660	80,098,765	74,416,680
Operating expenses		(85,975,582)	(77,390,244)	(42,698,075)	(40,139,351)
Administrative Expenses	20.00	(20,312,282)	(18,287,791)	(10,011,631)	(9,385,989)
Selling & Distribution Expenses	21.00	(65,663,300)	(59,102,453)	(32,686,444)	(30,753,362)
Operating Income		88,989,314	97,295,416	37,400,690	34,277,329
Financial expenses	22.00	(1,112,984)	(1,351,566)	(556,903)	(669,527)
Interest and Other income	23.00	4,971,971	7,578,426	2,434,228	3,780,853
Net Operating Profit		92,848,301	103,522,276	39,278,015	37,388,655
Worker's Profit Participation and Welfare Fund (WPP&WF)	24.00	(4,421,348)	(4,929,632)	(1,870,382)	(1,780,412)
Net Profit before Income Tax		88,426,953	98,592,644	37,407,633	35,608,243
Income Tax Expenses:	25.00	(19,536,988)	(24,462,680)	(7,628,066)	(8,694,809)
Current Tax Expenses	25.01	(17,531,297)	(22,812,104)	(7,054,013)	(7,994,115)
Deferred Tax expenses	25.02	(2,005,691)	(1,650,576)	(574,053)	(700,694)
Net Profit after tax		68,889,965	74,129,964	29,779,567	26,913,434
Other Comprehensive Income		-	-	-	-
Total comprehensive income for the period		68,889,965	74,129,964	29,779,567	26,913,434
Earnings Per Share (EPS)	26.00	0.50	0.54	0.22	0.20

The annexed notes (1-39) form an integral part of these financial statements.



Chairman



Managing Director



Director



Chief Financial Officer



Company Secretary

Place: Dhaka;

Dated: January 27, 2022

SILVA PHARMACEUTICALS LTD.
Statement of Changes in Equity
For the Half-Year ended 31 December, 2021

Particulars	<i>(Amount in Taka)</i>		
	Share Capital	Retained Earnings	Total
Balance as on 1st July, 2021	1,365,000,000	905,472,128	2,270,472,128
Net profit after tax during the period	-	68,889,965	68,889,965
Dividend Paid in Cash	-	-	-
Balance as at 31 December, 2021	1,365,000,000	974,362,093	2,339,362,093

For the Half-Year ended 31 December, 2020

Particulars	<i>(Amount in Taka)</i>		
	Share Capital	Retained Earnings	Total
Balance as on 1st July, 2020	1,365,000,000	833,109,877	2,198,109,877
Net profit after tax during the period	-	74,129,964	74,129,964
Dividend Paid in Cash	-	-	-
Balance as at 31 December, 2020	1,365,000,000	907,239,841	2,272,239,841


 Chairman


 Managing Director


 Director


 Chief Financial Officer


 Company Secretary


Place: Dhaka;
 Dated: January 27, 2022


SILVA PHARMACEUTICALS LTD.

Statement of Cash Flows

For the Half-Year ended 31 December, 2021

Particulars	Notes	Amount in Taka	
		01/07/2021 to 31/12/2021	01/07/2020 to 31/12/2020
Cash flows from Operating Activities			
Cash received from Customers	28.00	408,246,899	409,306,922
Cash received from non-operating income	29.00	6,802,793	10,391,183
Cash Paid to Suppliers	30.00	(199,200,679)	(231,701,684)
Cash Paid to Employees	31.00	(77,068,888)	(63,575,607)
Cash Paid for Others	32.00	(12,071,673)	(11,305,481)
Income Tax Paid	33.00	(14,418,693)	(19,932,749)
Net cash inflow/(outflow) from operating activities (A)	35.00	112,289,759	93,182,584
Cash flows from Investing Activities			
Acquisition of Property, Plant and Equipment	34.00	(53,465,139)	(6,486,295)
Cash Payments for Capital Work-in-progress		(61,439,200)	(46,155,586)
Cash received/Payments from/to FDR		(12,950,887)	(2,978,157)
Net cash used in investing activities (B)		(127,855,226)	(55,620,038)
Cash flows from Financing Activities			
Short Term Loan received/(Repaid)		(66,347)	8,661,132
Cash payment for Financial Expenses		(750,362)	(838,465)
Cash payment towards lease liabilities		(3,285,240)	(3,246,240)
Cash Dividend Paid		(31,827)	(551,640)
Net cash inflow from financing activities (C)		(4,133,776)	4,024,787
Net increase/(decrease) of Cash and Cash Equivalents (A+B+C)		(19,699,243)	41,587,333
Cash and Cash Equivalents at the beginning of the period		58,662,709	36,412,280
Cash and Cash Equivalents at the end of the period		38,963,466	77,999,613
Net Operating Cash Flow Per Share (NOCFPS)	35.00	0.82	0.68


Chairman


Managing Director


Director


Chief Financial Officer


Company Secretary

Place: Dhaka;

Dated: January 27, 2022